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Background: There is a lack of consensus regarding the risk of postoperative hemorrhage in patients on
antithrombotic therapy who undergo endoscopic submucosal dissection (ESD).
We examined postoperative bleeding rates and risk factors for postoperative hemorrhage from post-ESD gastric
ulcers in patients on antithrombotic therapy.
Methods: The subjects of this study were 833 patients who underwent ESD of gastric tumors. Of these,
743 were not on antithrombotic therapy and 90 were on some form of antithrombotic therapy (46 on
low-dose aspirin (LDA) only, 23 on LDA + thienopyridine, and 21 on LDA + warfarin). All patients commenced
proton pump inhibitor (PPI) therapy immediately postoperatively. Antiplatelet agents were discontinued
for 7 days preoperatively and postoperative Day 1, and anticoagulants for 5 days preoperatively and
postoperative Day 1.
Results: The postoperative bleeding rate in the antithrombotic group was 23.3%, significantly higher than the
2.0% observed in the non-antithrombotic group. Significant differences were seen in patients in the antithrombotic
group with and without postoperative bleeding according to ESD duration (p = 0.041), PPI + mucosal protective agent
combination therapy (p = 0.039), and LDA +warfarin combination therapy (p < 0.001). Multivariate analysis of these
factors yielded odds ratios of 1.04 for ESD duration, 14.83 for LDA +warfarin combination therapy, and 0.27 for
PPI +mucosal protective agent combination therapy.
Conclusions: The risk of postoperative hemorrhage following gastric ESD was higher in patients with
antithrombotic therapy than in those without that therapy. Among these patients, LDA + warfarin combination
therapy and longer ESD duration were significant risk factors for postoperative bleeding. On the contrary, a
mucosal protective agent to PPI therapy, lowering the odds ratio for postoperative bleeding, which suggests that
the addition of a mucosal protective agent might be effective in preventing post-ESD hemorrhage in patients on
antithrombotic therapy.
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Endoscopic submucosal dissection (ESD) is increasingly
used worldwide in the treatment of gastric tumors. How-
ever, postoperative complications of ESD, including
perforations of the upper gastrointestinal tract and
post-ESD ulcer bleeding (postoperative hemorrhage),
are increasingly becoming a problem. Whereas perfora-
tions are mainly a problem with technique, postoperative
hemorrhage is a serious complication that occurs in a
certain proportion of patients irrespective of technical
considerations. Studies concerning post-ESD ulcer healing
and postoperative hemorrhage have reported that proton
pump inhibitor (PPI) therapy gives good healing rates
for post-ESD ulcers, and that it is also effective in
preventing postoperative hemorrhage [1,2], so PPIs are
widely administered post-ESD.
With the advance of the ageing society, we are increas-
ingly likely to perform ESD in patients with concurrent
medical conditions, in particular heart conditions and
cerebrovascular disease. Many of these patients are on
long-term antithrombotic therapy (antiplatelet agents or
anticoagulants). Patients on antiplatelet agents such as
low-dose aspirin (LDA) have a greater risk and frequency
of upper gastrointestinal hemorrhage, and Luis et al. [3]
reported adjusted relative risks for upper gastrointestinal
hemorrhage of 1.79 for LDA monotherapy, 3.71 for
LDA + thienopyridine, and 3.62 for LDA + anticoagulant
combination therapy. Furthermore, inhibitors of acid
secretion such as PPIs have been reported to be effective
in reducing the incidence and prevalence of upper
gastrointestinal hemorrhage [4-6].
For less invasive endoscopic procedures such as biop-
sies, the risk of bleeding increases very little in patients
taking antiplatelet agents [7-9], and even in patients on
anticoagulant therapy the risk of postoperative hemor-
rhage is unchanged as long as the prothrombin time-
international normalized ratio (PT-INR) is under 3.0
[10,11]. There is, however, a lack of consensus regarding
more invasive procedures such as ESD.
In this study, we examined the rates of postoperative
bleeding from post-ESD gastric ulcers following ESD for
gastric tumors in accordance with a protocol specifying
uniform rules for cessation and recommencement of
antithrombotic therapy, in a retrospective study. We also
investigated the risk factors for such bleeding in a case–
control study to provide effective prophylaxis.
Methods
Patients
The subjects were 833 patients who underwent ESD for
gastric tumors (616 with early gastric cancers, 217 with
gastric adenomas) at the Osaka Medical College Hospital
between June 2002 and October 2012. We use the over-
all term antithrombotic therapy to include therapy withantiplatelet agents (LDA, thienopyridines) and antico-
agulants (warfarin potassium). Antiplatelet agents were
administered as monotherapy (one or two agents) or in
combination with an anticoagulant. The study included
patients with a history of cerebral infarction following
surgery for valvular disease. Accordingly, all patients on
anticoagulants were also on antiplatelet agents, and none
were on anticoagulant monotherapy. We compared
hemorrhage rates between the antithrombotic and non-
antithrombotic groups after ESD. We also examined risk
factors for such bleeding in the antithrombotic group as
a case–control study.
ESD
We used a VIO 300 D (ERBE Elektromedizin, Tübingen,
Germany) high-frequency electrosurgical generator. Ap-
proximately 5 mm outside the lesion margin, we placed
markings with a needle knife (KD-1 L; Olympus Medical
Systems Co. Ltd, Tokyo, Japan) [12] using a coagulation
wave (Soft Coag, Effect 7, 60 W). Next we injected 0.05%
adrenaline in physiological saline into the area to be
excised, between the muscularis propria and the mucosa to
give adequate mucosal elevation. The precut was perfor-
med using mainly the needle knife and a cutting wave
(Endo Cut I, Effect 2, Duration 3, Interval 3), and the
circumferential cut using mainly an IT Knife2 electrosurgi-
cal knife (KD-611 L; Olympus) [13] and a cutting wave
(Endo Cut Q, Effect 2, Duration 4, Interval 3). Submucosal
dissection was similarly performed using the IT Knife2,
essentially using a coagulation wave (Swift Coag, Effect 2,
60–70 W) in conjunction with a cutting wave (Endo Cut
Q, Effect 2, Duration 4, Interval 3) for difficult-to-dissect
areas with marked fibrosis. For intraoperative bleeding, if
oozing occurred, hemostasis was first attempted using a
coagulation wave (Swift Coag, Effect 3, 60–80 W), still
using the IT Knife2. If this was ineffective, hemostasis was
achieved by pinpoint grasping of the bleeding source with
hemostatic forceps (FD-410LR; Olympus) and a soft coa-
gulation wave (Soft Coag, Effect 6, 80 W). Similarly, for
arterial spurting, the hemostatic forceps were used, and if
the heat was not adequately transferred to the bleeding
vessel with soft coagulation, hemostatic forceps with a
larger contact area (Radial Jow 3 HOT; Boston Scientific,
Marlborough, USA) were substituted and hemostasis
was achieved with a high-output coagulation wave
(Forced Coag, Effect 2, 40 W) for 1–2 s.
Following resection of the lesion, to prevent postoper-
ative hemorrhage all blood vessels visible in the ulcer
base were treated with a coagulation wave (Soft Coag,
Effect 6, 80 W) using hemostatic forceps.
Treatment of post-ESD ulcer
For all patients, perioperative management was conducted
in accordance with the ESD clinical protocol of this
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1, whether they were on antithrombotic therapy or not,
patients were fasted until Day 2, and allowed to eat
from Day 3. Intravenous PPI therapy (omeprazole 40 mg/
day) was commenced immediately postoperatively. Pa-
tients underwent EGD on Day 2 to confirm hemostasis,
and if necessary any blood vessels visible in the ulcer
base were cauterized using a soft coagulation wave
(Soft Coag, Effect 6, 80 W). After resumption of oral
feeding on Day 3, patients were commenced on an oral
PPI (rabeprazole 10 mg/day). Patients regularly taking
mucosal protective agents prior to undergoing ESD, e.g.,
for chronic gastritis, were asked to discontinue them on
Days 1 and 2 and recommence them on Day 3 (Figure 1).
Guidelines for cessation and recommencement of
antithrombotic therapy
After confirming with the prescribing physician whether
antithrombotic therapy could be discontinued, ESD was
performed only on patients able to discontinue anti-
thrombotic therapy. The protocol for antiplatelet agents
was to discontinue them from Day −6 to Day 2, and for
anticoagulants to discontinue them from Day −4 to Day 2.
Heparin (unfractionated heparin 10000–20000 U conti-
nuous venous infusion) was substituted for anticoagulants
while the latter were discontinued, with measurement of
the activated partial thromboplastin time (APTT) as
appropriate and maintenance of the APTTat roughly twice
the preheparinization level. In view of the risk of thrombo-
embolic disease, antiplatelet agents were recommenced asFigure 1 Endoscopic submucosal dissection protocol. For all patients, t
until Day 2 and allowed to eat from Day 3. After resumption of oral feedin
regularly taking mucosal protective agents prior to undergoing ESD were a
Day 3. The protocol for antiplatelet agents was to discontinue them from D
from Day −4 to Day 2. Heparin was substituted for anticoagulants while th
preheparinization level. Antiplatelet agents were recommenced as soon as
by EGD on Day 2. Anticoagulants were similarly recommenced on postope
returned to a therapeutic level.soon as possible on postoperative Day 3, following
confirmation of hemostasis by EGD on Day 2. Antico-
agulants were similarly recommenced on postoperative
Day 3, and heparin was discontinued once the PT-INR
had returned to a therapeutic level (Figure 1).Definition of postoperative hemorrhage
We performed EGD for all patients on Day 2, and no
patient showed bleeding. All the patients resumed taking
antithrombotic agents on Day 3. Therefore, postoperative
hemorrhage was defined as hematemesis and/or melena
or a sudden drop in hemoglobin (Hb) ≥ 2 mg/dL occur-
ring after recommencing eating on Day 3, requiring an
unscheduled EGD, at which bleeding was confirmed to
be from the post-ESD ulcer.Statistical analysis
Categorical data were compared using the χ2 test (with
Yates’ correction) or Fisher’s exact test. Differences in the
means of continuous data were compared using Student’s
t-test or the Mann–Whitney U-test. To identify important
risk factors for post-ESD bleeding, predictors with p < 0.2
in the univariate analysis were included in a backward
stepwise multiple logistic regression model. p < 0.05 was
considered significant, and all tests were two-sided.
Data are expressed as mean ± SD or as median (range).
All statistical analyses were performed using PASW
Statistics 18 for Windows (SPSS Japan, Tokyo).he day of the ESD procedure was set as Day 1. Patients were fasted
g on Day 3, patients were commenced on an oral PPI. Patients
sked to discontinue them on Days 1 and 2 and recommence them on
ay −6 to Day 2, and that for anticoagulants was to discontinue them
e latter were discontinued, maintaining the APTT at roughly twice the
possible on postoperative Day 3, following confirmation of hemostasis
rative Day 3, and heparin was discontinued once the PT-INR had
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All patients received oral and written explanation of the
study prior to participation and gave written informed
consent. The study was conducted in accordance with
the Declaration of Helsinki (1995) after the protocol had
been approved by the Ethics Review Committee of
Osaka Medical College.
Results
There were 743 patients in the non-antithrombotic group
and 90 in the antithrombotic group. The underlying
disease in the antithrombotic group was a cardiac condi-
tion in 77.8% (70/90) and cerebrovascular disease in 22.2%
(20/90). There were 46 patients on LDA (Bayaspirin®)
monotherapy, 23 on LDA + thienopyridine (Panaldine®,
clopidogrel), and 21 on LDA +warfarin (Figure 2).
No significant differences were seen between the
non-antithrombotic and antithrombotic groups in any
background factors: age, gender, Helicobacter pylori
(H. pylori) infection rate, tumor size, tumor site, tumor
morphology, prevalence of concurrent disease (diabetes,
renal failure or cirrhosis), or use of mucosal protective
agents. However, the postoperative bleeding rate in the
antithrombotic group was 23.3% (21/90) at a median
5.5 days (range 3–15 days), significantly higher than
that of 2.0% (15/743) in the non-antithrombotic group
at a median 3.5 days (range 3–10 days) (p < 0.001). There
was only one reported thromboembolytic episode (1.1%),
a case of cerebral infarction (Table 1).
Comparison of the 21 patients who experienced post-
operative hemorrhage and the 69 who did not out of
the 90 patients on antithrombotic therapy revealed noFigure 2 Study outline. There were 743 patients in the non-antithrombot
in the antithrombotic group was a cardiac condition in 77.8% (70/90), and
LDA monotherapy, 23 on LDA + thienopyridine and 21 on LDA +warfarin.significant differences in any background factors: age,
gender, tumor size, tumor site, H. pylori infection rate,
prevalence of concurrent disease (diabetes, renal failure
or cirrhosis), or number of antiplatelet agents (LDA only
or LDA + thienopyridine) (p > 0.05). However, significant
differences were seen according to ESD duration, LDA +
warfarin combination therapy, and PPI + mucosal pro-
tective agent combination therapy (17 patients were on
rebamipide 300 mg/day, 8 on teprenone 150 mg/day, 5 on
ecabet sodium hydrate 2.0 g/day, and 4 on irsogladine
maleate 4 mg/day) (Table 2). Multivariate analysis of
these factors yielded odds ratios of 1.04 for ESD duration
(95% CI 1.01–1.08, p = 0.025), 14.83 for LDA +warfarin
combination therapy (95% CI 3.91–56.26, p < 0.001), and
0.27 for PPI + mucosal protective agent combination
therapy (95% CI 0.07–1.02, p = 0.054) (Table 3).
Discussion
In this study we found that, among patients undergoing
gastric ESD, the risk of postoperative bleeding was higher
in those on antithrombotic therapy than in those not on
antithrombotic therapy. Although there was no significant
difference between postoperative bleeding rates in the
LDA monotherapy and LDA + thienopyridine combin-
ation therapy groups, LDA +warfarin combination ther-
apy was an extremely strong risk factor for post-ESD
bleeding. In the study, we investigated for the first time
the risk of hemorrhage following gastric ESD in patients
on antithrombotic therapy on the basis of a protocol
setting out the timing of their discontinuation and recom-
mencement of antithrombotic therapy, as well as the risk
associated with different antithrombotic agents.ic group and 90 in the antithrombotic group. The underlying disease
cerebrovascular disease in 22.2% (20/90). There were 46 patients on
Table 1 Characteristics of non-antithrombotic and antithrombotic groups
Non-antithrombotic (n = 743) Antithrombotic (n = 90) p value
Age(yr) 65.3 ± 12.3 64.8 ± 13.7 0.719
Gender(M?F)(%M) 423/320(56.9) 54/36(60.0) 0.578
H. pylori infection (+/−)(%positive) 587/156(79.0) 73/17(81.1) 0.642
Tumor sixe(mm) 15.5 ± 5.2 15.7 ± 5.5 0.731
Tumor type
IIa 430 51
0.976IIa + IIc 112 14
IIc 201 25





Concrurrent disease(diabetes, renal failure, cirrhosis)(+/−)(%positive) 240/503(32.3) 28/62(31.1) 0.819
Gastroprotective agent(+/−)(%positive) 315/428(42.4) 39/51(43.3) 0.865
post-ESD bleeding(+/−)(%positive) 15/728(2.0) 21/69(23.3) <0.001※
ESD endoscopic submucosal dissection.
※p < 0.05 vs non-bleeding. Ratios were analysed using the χ2 test.
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guidelines for the management of antithrombotic agents
for endoscopic procedures published in 2009 recommend
that LDA therapy be continued for gastrointestinal
endoscopies, even for procedures with a high risk of
hemorrhage [14]. On the other hand, the corresponding
European Society of Gastrointestinal Endoscopy guide-
lines published in 2011 state that, in principle, LDA
should be continued for most endoscopies but recom-




















ESD endoscopic submucosal dissection, LDA low-dose aspirin.
※p < 0.05 vs non-bleeding. Ratios were analysed using the χ2 test.procedures with a high risk of hemorrhagic complications,
provided the risk of thromboembolic events is low [15].
In this study, after confirming with the prescribing
physician that antithrombotic agents could be discon-
tinued, we performed ESD on patients at low risk of
thromboembolic events following a set period of dis-
continuation of antithrombotic agents. There was only
one reported thromboembolytic episode (1.1%) attrib-
utable to cessation of antithrombotic therapy. When a
patient on LDA therapy discontinues aspirin for aboutatus on antithrombotic group
Bleeding (n = 21) Non-bleeding (n = 69) p value
65.4 ± 13.4 64.7 ± 13.8 0.838
12/9(57.1) 42/27(60.9) 0.760
17/4(81.0) 56/13(81.2) 0.983














Table 3 Significant predictors of post-ESD bleeding
identified by using multiple logistic regression
Parameter Odds ratio 95% CI p value
Duration of ESD 1.04 1.01-1.08 0.025※
LDA +warfarin 14.83 3.91-56.26 <0.001※
PPI + gastroprotective agent 0.27 0.07-1.02 0.054
※p < 0.05.
ESD endoscopic submucosal dissection, LDA low dose aspirin, PPI
proton-pump inhibitor.
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ischemic attack is 3.29 (95% CI 1.07–9.80, p < 0.005)
[16]. In this study, we discontinued LDA either for a
shorter period or not at all, so as to keep the incidence
of cerebral infarction to a relatively low level. However,
the postoperative bleeding rate in the antithrombotic
group was 23.3%, significantly higher than the 2.0% ob-
served in the non-antithrombotic group.
There is a lack of clear evidence of the extent to which
hemorrhagic complications are increased in patients on
antiplatelet + anticoagulant combination therapy under-
going gastrointestinal endoscopic procedures with a
high risk of bleeding. In a retrospective study of 5593
patients undergoing colorectal polypectomy, postoperative
hemorrhage was significantly more common in patients
on warfarin therapy [17]. From this, it goes without say-
ing that warfarin should be discontinued for colorectal
polypectomy, and the recommendation for ESD, with
its high incidence of hemorrhagic complications, is to
discontinue warfarin and replace it with heparin [18].
We also replace warfarin with heparin, monitoring APTT
as we perform the procedure. Patients on warfarin therapy
undergoing ESD in this study included some with a
history of cerebral infarction following surgery for
valvular disease, so all patients on warfarin were also
on LDA. Because there were no patients on warfarin
monotherapy in this study, it is uncertain whether the risk
of postoperative bleeding was increased by LDA +warfarin
combination therapy or by warfarin alone. However,
the postoperative bleeding rate was significantly higher
in patients on LDA +warfarin combination therapy, with
an odds ratio of 14.83 (p < 0.001), confirming combination
therapy to be an extremely strong risk factor. The odds
ratio for postoperative bleeding in patients taking mucosal
protective agents in addition to a PPI was 0.27 (p = 0.054),
suggesting that the addition of a mucosal protective agent
may be effective in preventing postoperative hemorrhage,
although the difference was not significant. To date,
only four studies worldwide have examined the rela-
tionship between antithrombotic therapy and bleeding
following gastric ESD.
In 2009, Ono et al. [19] published a retrospective study
of gastric ESD in patients on antithrombotic therapy.
They reported a postoperative bleeding rate of 10.7%(6/56) in patients on antithrombotic therapy and 5.2%
(20/388) in patients not on antithrombotic therapy,
with no significant difference between the groups. All
patients on antithrombotic therapy were also taking an
antiplatelet agent, with 5 on combination therapy with
an anticoagulant. Of these, only 3 were heparinized. All
patients discontinued antithrombotic therapy for 1 week
before and after ESD. The reason for the lack of a sig-
nificant difference in the postoperative bleeding rate
between patients on antithrombotic therapy and those
not on antithrombotic therapy may be because the drug
withdrawal period was longer than for the present
study. Considering the risk of thromboembolic events,
however, antithrombotic therapy should be recommenced
as soon as possible, once hemostasis has been confirmed
endoscopically. The standards for cessation and recom-
mencement of antithrombotic therapy, as well as hepari-
nization, are vague and ambiguous.
In 2010, Mannen et al. [20] published a retrospective
study of risk factors for complications following ESD in
436 patients with gastric tumors. They reported a post-
operative bleeding rate of 3% (1/33) in patients on
antithrombotic therapy and 9.4% (38/403) in patients
not on antithrombotic therapy, with no significant dif-
ference between the groups.
In a similar retrospective study published in 2011,
Okada et al. [21] reported risk factors for post-ESD
bleeding in 582 patients with gastric tumors. They
reported a postoperative bleeding rate of 14.2% (4/28) in
patients on antithrombotic therapy and 12.6% (70/554) in
patients not on antithrombotic therapy, with no evidence
for a causal relationship between postoperative bleeding
and antithrombotic therapy (p = 0.7732).
However, these studies do not report in detail whether
patients were on antiplatelet agents only or combination
therapy with an anticoagulant, the timing of cessation
and recommencement of antithrombotic therapy, or
whether heparin was substituted.
A study that found that antithrombotic therapy in-
creases the risk of postoperative bleeding was the 2010
retrospective study by Tsuji et al. [22] of gastric ESD
in patients on antithrombotic therapy, as well as corti-
costeroids and nonsteroidal anti-inflammatory drugs
(NSAIDs). They reported a postoperative bleeding rate
of 34.8% (8/15) in patients on antithrombotic therapy
and 16% (60/315) in patients not on antithrombotic
therapy, significantly higher in the former with an odds
ratio of 2.76 (95% CI 1.09-6.98). As in the present study,
they followed a protocol with set timing of cessation
and recommencement of antithrombotic therapy, and
heparinization for patients on anticoagulant therapy, and
they reported an increased risk of post-ESD bleeding in
patients on antithrombotic therapy. However, corticoste-
roids and NSAIDs are included among the antithrombotic
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arately, so simple comparisons cannot be made.
On the other hand, suppressors of acid secretion, hista-
mine type-2 receptor antagonists and PPIs, were used
to treat post-ESD ulcers in the above four studies, but
gastroprotective agents were not used. In this study,
although multivariate analysis did not show a significant
difference (odds ratio: 0.27, p = 0.054) in combination
therapy with a mucosal protective agent and a PPI, uni-
variate analysis showed significant differences (p = 0.039)
between the two groups. For the first time we added these
results suggest that the addition of a mucosal protective
agent may be effective in preventing post-ESD hemor-
rhage in patients on antithrombotic therapy.
In the treatment of hemorrhagic peptic ulcers, sup-
pressors of acid secretion such as PPIs promote ulcer
healing as well as reducing the risk of hemorrhage
[23,24]. On the other hand, in the treatment of post-
ESD ulcers, PPI +mucosal protective agent combination
therapy is reported to yield better healing rates and simi-
lar postoperative bleeding rates as PPI monotherapy
[25,26]. These studies report no significant difference
between postoperative bleeding rates in the PPI group
and PPI +mucosal protective agent group, but the studies
were conducted with patients not on antithrombotic
therapy. In this study, we included patients on anti-
thrombotic therapy, and the fact that our results show
a reduction in postoperative bleeding can be attributed
to a superior promotion of ulcer healing with PPI +muco-
sal protective agent combination therapy, as demonstrated
in the earlier studies.
Asian people are generally considered to have lower
gastric acid levels than Westerners [27-29], and further-
more differentiated type gastric cancers, one of the indi-
cations for ESD, show a markedly atrophic background
mucosa associated with H. pylori infection. From this
we can assume impairment of gastric mucin and other
protective factors, as well as reduced acid secretory
function. We can also infer that the pharmacological
properties of mucosal protective agents exert favorable
effects on the post-ESD healing process, including pre-
vention of postoperative hemorrhage.
The tendency towards higher postoperative bleeding
rates with longer ESD durations can be explained in
terms of a longer time taken to achieve hemostasis while
resecting the lesion. When multiple vessels require cau-
tery, it follows that a number of vessels are present in
the ulcer floor following ESD, and we can assume that
this influences the postoperative bleeding rate.
The limitations of this study are that it was a retrospective
study, that we did not perform ESD while continuing
antithrombotic therapy, the absence of a warfarin monother-
apy group, and the possibility of a bias in the administration
of mucosal protective agents. We are a tertiary referralcenter, resulting in a relatively high proportion of patients
with background factors such as cerebral infarction
following valvular surgery. All patients on warfarin ther-
apy were also taking LDA, so that we had no warfarin
monotherapy group for comparison. We were unable to
identify any earlier studies that examined this area in
detail based on a consistent protocol, and we believe
the next step should be to conduct a prospective study on
the basis of our results. PPI monotherapy is the stand-
ard treatment for post-ESD ulcers, but the risk of post-
operative hemorrhage cannot be avoided through a PPI
alone in patients on antithrombotic therapy. Our results
indicate that the addition of a mucosal protective agent to
PPI therapy may reduce the risk of postoperative hem-
orrhage, potentially an extremely useful finding. We intend
to conduct a large-scale prospective trial to confirm this.
Conclusions
The risk of postoperative hemorrhage following gastric
ESD was higher in patients with antithrombotic therapy
than in those without that therapy. Among these patients,
LDA + warfarin combination therapy and longer ESD
duration were significant risk factors for postoperative
bleeding. On the contrary, a mucosal protective agent to
PPI therapy, lowering the odds ratio for postoperative
bleeding, which suggests that the addition of a mucosal
protective agent might be effective in preventing post-ESD
hemorrhage in patients on antithrombotic therapy. A
further prospective study with a large sample will be
needed to confirm these.
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